Latest Oncology News

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

November 30th 2021

Kristi Rosa

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

November 30th 2021

Courtney Marabella

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

November 30th 2021

Gina Mauro

The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

November 30th 2021

Jessica Hergert

The Japan Pharmaceuticals and Medical Devices Agency has approved the PD-1 inhibitor pembrolizumab for frontline use in combination with 5-fluorouracil plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma.

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup

November 30th 2021

Caroline Seymour

The combination of pembrolizumab and axitinib demonstrated comparable activity and safety vs sunitinib in Japanese patients vs the global population of patients with newly diagnosed metastatic renal cell carcinoma enrolled in the phase 3 KEYNOTE-426 trial.

Latest Oncology Videos

All Oncology News

New ASTRO President Calls Attention to In-Person Meetings, Remaining Challenges, and Ongoing Research in Radiation Oncology

November 24th 2021

Jessica Hergert

Jeff M. Michalski, MD, MBA, FASTRO, shares his presidential goals for ASTRO, the success of the hybrid 2021 ASTRO Annual Meeting, and remaining questions in radiation oncology that research efforts are poised to address.

FDA Greenlights Maribavir for Select Post-Transplant Recipients With CMV

November 24th 2021

Kristi Rosa

The FDA has approved maribavir for the treatment of adult and pediatric patients aged 12 years and older weighing at least 35 kg who have post-transplant cytomegalovirus infection that does not respond to available antiviral treatment.

Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

November 24th 2021

Bijal Shah, MD, Moffit Cancer Center

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, Moffit Cancer Center

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Dr. Shah and Dr. Wang on Managing CRS and Neurotoxicity in Leukemia/Lymphoma

November 24th 2021

Bijal Shah, MD, Moffit Cancer Center

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, Moffit Cancer Center

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

World Health Organization Taps Sylvester in Global Fight Against Cervical Cancer

November 24th 2021

Sylvester Comprehensive Cancer Center will provide a leading role in the collaborative effort to eliminate the preventable disease that kills thousands of women around the world.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana A. Leal, MD

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Dr. Erickson on PARP Inhibitor Maintenance Therapy in BRCA-Mutated Ovarian Cancer

November 24th 2021

Britt Erickson, MD

Britt Erickson, MD, discusses the benefit of PARP inhibitor maintenance therapy in patients with BRCA-mutated ovarian cancer.

Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma

November 24th 2021

Courtney Marabella

Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial with relatlimab and nivolumab, and the phase 3 KEYNOTE-716 trial with pembrolizumab, cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes.

Incorporating Mutational Panel Testing Remains Crucial in MDS

November 24th 2021

Maggie Tibbitt

David Sallman, MD, discusses incorporating mutational testing of patients with myelodysplastic syndrome into clinical practice, and strategies that can be utilized to treat this population.

Home Infusion Trend Stirs Debate

November 24th 2021

Meir Rinde

The COVID-19 pandemic spurred the launching or expansion of in-home cancer therapy infusion programs at several oncology centers around the United States, drawing a surge of interest throughout the field as well as opposition from oncologists who are concerned about the implications for patient safety and the potential impact on community practices that provide in-house infusion services.

Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line

November 24th 2021

Bradley J. Monk, MD, FACOG, FACS

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

ONCT-216 Shows Encouraging Efficacy, Safety in Relapsed/Refractory Ewing Sarcoma

November 24th 2021

Kristi Rosa

The targeted small molecule inhibitor of the E26 transformation-specific family of oncoproteins, ONCT-216, produced notable response and disease control rates when delivered at the recommended phase 2 dose to heavily pretreated patients with Ewing sarcoma.

Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer

November 24th 2021

Bradley J. Monk, MD, FACOG, FACS

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

See All News